Abstract: Objective To investigate the role of oxidative stress in itch-indicative scratching behavior in mice, and furthermore, to define the cellular and molecular mechanisms underlying oxidative stress-mediated itch. Methods Scratching behavior was induced by intradermal injection of the oxidants hydrogen peroxide (H 2 O 2 ) or tert-butylhydroperoxide Oxidative stress by different oxidants induces profound scratching behavior, which is largely histamine-and TRPV1-independent but TRPA1-dependent. Antioxidants and TRPA1 antagonists may be used to treat human itch conditions associated with oxidative stress.
Introduction
Itch (pruritus) is defined as an unpleasant sensation that elicits the desire or reflex to scratch. Acute itch serves as a warning and is a self-protective mechanism against potentially harmful irritations [1] . However, chronic itch is a common clinical problem associated with skin diseases (e.g., atopic dermatitis and psoriasis) [2, 3] , systemic diseases (e.g., chronic renal failure and cholestasis) [4, 5] , and metabolic disorders (e.g., diabetes) [6] . Although the itch sensation can be transiently relieved by scratching [7] , itchscratch cycles often exacerbate cutaneous problems and lead to further injury [8] . Histamine is one of the best-studied itch mediators, and antihistamines serve as the first clinical choice for treating itch [9, 10] . However, most types of chronic itch are resistant to antihistamine treatment [11] . Chronic itch substantially reduces the quality of life of affected individuals [12, 13] . Thus, it is urgent to identify novel mediators and the signaling pathways involved in the pathogenesis of itch, in order to provide new targets for anti-pruritic treatment.
Oxidative stress is chemically associated with overproduction of reactive oxygen species (ROS) or reduction in the capability of antioxidant defense [14] . In humans, oxidative stress has long been proposed to contribute to the pathogenesis of systemic and metabolic, cardiovascular and neurodegenerative diseases [14] [15] [16] [17] . Oxidative stress and ROS have been strongly implicated in the pathogenesis of inflammatory and neuropathic pain [18, 19] . Of interest, recent studies have proposed different mechanisms for pain and itch [11, [20] [21] [22] [23] . However, the relationship between oxidative stress and itch has not been investigated. Strikingly, chronic itch commonly accompanies many oxidative stress-mediated diseases, such as atopic dermatitis, psoriasis, chronic renal failure, cholestasis, and diabetes [24] [25] [26] .
The aim of the present study was to test whether oxidative challenges induce itch-associated behaviors and further elucidate the underlying molecular and cellular mechanisms. In animal studies, itch can be quantitatively evaluated by measuring the scratching behavior elicited by itch-evoking agents [20, [27] [28] [29] [30] . In this study, scratching responses in mice were induced by intradermal (i. HC-030031 was dissolved in 20% DMSO. Trolox was prepared in 1 mol/L NaHCO 3 , and the pH was adjusted to 7.0 with 1 N HCl. The solution was diluted with PBS to obtain the desired concentrations.
Animals
Male adult CD1 mice (8-10 weeks) were purchased from Charles River (Wilmington, MA, USA).
C57BL/6 wild-type and Trpv1 and Trpa1 knockout mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) [31] . Animals were housed at controlled room temperature (22 ± 2°C) with 60%-80% humidity under a 12 h∶12 h light/dark cycle. Food and water were available ad libitum except during experiments. In all the behavioral tests, the observer was blinded to the treatment or genotype of the animals. All animal experimental procedures were performed in accordance with the guidelines of the International Association for the Study of Pain and the protocol was approved by Harvard Medical School Animal Care Committee.
Itch behavioral testing
As described previously [22] , Mice were returned to their chambers immediately after the injection and scratching behavior was quantified by counting the number of scratches during 30 min. A scratch was counted when the mouse lifted its hindpaw to scratch the shaved region and returned the paw to the floor or to the mouth for licking.
Cheek model To simultaneously distinguish itch
and pain responses, we used the cheek model by injection of chemical into the cheek [32, 33] . The cheeks of mice were shaved (about 5 × 8 mm 
Tail immersion test
As previously described [34] , the tail immersion test was used to assess heat pain sensitivity.
Briefly, the terminal 3 cm of the tail was immersed in a hot water bath at 52°C and the latency of tail-flick was recorded, with a cutoff time of 10 s to avoid tissue injury. tively, in ascending order), one week before oxidant injection, as described previously [22] .
Pharmacological treatments
To assess the involvement of transient receptor potential subtype ankyrin 1 (TRPA1) in oxidant-induced scratching behavior, HC-030031 (10 or 20 μg in 50 μL vehicle), the selective TRPA1 antagonist [35] , was co-administered i.d. with 0.3% H 2 O 2 . HC-030031 was dissolved in 20% DMSO.
Statistical analysis
All data are expressed as mean ± SEM, and were analyzed with Student's t test or one-way ANOVA followed by Bonferroni post-hoc test. P <0.05
was considered statistically significant. However, the highest concentration of H 2 O 2 (1%) induced fewer scratches than 0.3% (P <0.05), exhibiting an inverted U-shaped dose-response curve (Fig. 1A) , as shown for other pruritogens such as imiquimod [22] and chloroquine [11] .
Results

Oxidants induced robust scratching behavior in mice
The concentration of 0.3% H 2 O 2 was, therefore, chosen for the subsequent experiments. H 2 O 2 -induced scratching occurred rapidly in the first 5 min, peaked after 15 min, and declined thereafter (Fig. 1B) . Besides, no abnormal behaviors were observed after administration of H 2 O 2 .
Similarly, the oxidant tBHP ( Time course analysis showed that tBHP-elicited scratching was significant within 5 min, reached a peak at 10 min and maintained at 30 min (Fig. 1D) . Also, no abnormal behaviors were observed in the tBHP-treated mice.
Oxidants elicited wiping and scratching in the cheek model In order to simultaneously distinguish itch
and pain responses, we used the model of i.d. injection of oxidants into the cheek rather than the neck [32] . In this model, injection of pain-inducing agents, such as capsaicin, only elicits wiping behavior by the forelimb, while injection of itch-inducing agents, such as histamine, only elicit scratching behavior by the hindlimb [32] . Injection of H 2 O 2 (0.3% in 10 μL saline) or tBHP (2 μmol in 10 μL saline) into the cheek elicited both wiping and scratching behavior, indicating that these oxidants induced mixed pain and itch sensations at these doses (Fig. 2) . Notably, both H 2 O 2 and tBHP induced much more scratching than wiping behavior, suggesting that itch may be the major sensory modality induced by oxidants.
Opioid receptor antagonist suppressed oxidantinduced scratching We tested whether oxidant-induced
scratching is modulated by μ-opioid receptors, which have been implicated in itch in animals and humans [36] .
Morphine (1 mg/kg, i.p.), a μ-opioid receptor agonist, increased the latency of tail-flick in the hot water immersion test, showing its analgesic effect (Fig. 3A) . In contrast, the same dose of morphine did not reduce H 2 O 2 -or tBHPinduced scratching behavior (Fig. 3B) , consistent with clinical observations that morphine only reduces pain but not itch [37] . This result also suggests that H 2 O 2 -or tBHPinduced scratching is itch-associated, rather than painlike behavior in mice. We chose a low dose of morphine because higher doses (e.g., 5-10 mg/kg) can induce psychoactive behaviors which may interfere with scratching behavior [38] . Of note, naloxone (1 mg/kg, i.p.), an opioid receptor antagonist, attenuated the scratching induced by H 2 O 2 or tBHP ( Fig. 3B ; P <0.05, Student's t test), suggesting that endogenous opioids may be involved in H 2 O 2 -and tBHP-induced itch in mice.
Oxidant-induced scratching behavior was histamineindependent
Chlorpheniramine, a histamine H1 recep- tor antagonist [21] , was used to assess the involvement of histamine, one of the best-known itch mediators stored in and released from skin mast cells, in oxidant-induced itch.
As expected, chlorpheniramine (10 mg/kg, i.p.) blocked scratching induced by i.d. injection of histamine (Fig. 4) .
Nonetheless, chlorpheniramine at the same dose did not inhibit the scratching response induced by H 2 O 2 or tBHP (Fig. 4) . Thus, oxidative challenge-elicited scratching behavior is histamine-independent.
TRPV1-expressing C-fibers, but not TRPV1 per se,
were required for oxidant-induced scratching behavior It is well-established that TRPV1-expressing C-fibers mediate the itch sensation induced by various pruritogens [39] [40] [41] .
To determine the role of these fibers in oxidant-induced itch, we used systemic pretreatment with RTX, an ultrapotent TRPV1 agonist, to destroy TRPV1-expressing C-fibers, based on our previous work [22] . RTX-treated mice were insensitive to noxious heat (52°C water bath), demonstrating functional loss of these fibers (Fig. 5A) 5C ). Together, these results suggest that TPRV1-expressing C-fibers, but not TRPV1 per se, are required for oxidantinduced scratching behavior in mice.
TRPA1 was required for oxidant-induced scratching
behavior Recent work suggested that TRPA1 is essential for histamine-independent, Mas-related G protein-coupled receptor (Mrgpr)-mediated itch in mice [42] . Given the fact that H 2 O 2 activates TRPA1 [43, 44] , we then examined the role of TRPA1 in oxidant-induced scratching behavior, using pharmacological and genetic manipulations. Co-administration of H 2 O 2 and HC-030031, a selective TRPA1 antagonist, dose-dependently attenuated H 2 O 2 -induced scratching behavior (Fig. 6A) . Consistently, H 2 O 2 -induced scratching behavior was also substantially reduced in Trpa1 -/-compared to wild-type mice (Fig. 6B) . Together, these data suggest that TRPA1 plays a critical role in oxidant-induced pruritus. (Fig. 7A, B) . Thus, oxidant-induced scratching behavior can be attenuated by antioxidants.
Antioxidants attenuated oxidant-induced itch
Discussion
Itch is a major somatic sensation and can be acute (e.g., mosquito bite) or chronic (e.g., atopic dermatitis). Although acute itch is self-protective and serves as a warning system, chronic itch is a common clinical problem, for which consistent and effective therapeutics are still lacking [45, 46] .
Antihistamines serve as the standard treatment for clinical itch; however, most types of chronic itch are resistant to them [45] . Recent studies have identified several novel itch mediators that are largely independent of histamine [47] [48] [49] .
To our knowledge, this is the first study to demonstrate that oxidative challenges induce scratching behavior indicative of itch. We showed that TRPA1, but not TRPV1, mediated oxidant-elicited itch in mice. We further demonstrated that antioxidants substantially attenuated oxidant-induced itch responses. Thus, we offer novel mouse models of itch elicited by oxidative stress and these models should be useful for testing new anti-pruritic drugs and investigating the molecular and cellular mechanisms of oxidative stressinduced itch that are associated with chronic itch conditions in humans.
Great progress has been made in recent years, revealing a distinct molecular basis for the itch sensation [11, 20, 21, [49] [50] [51] . Primary sensory neurons located in the trigeminal and dorsal root ganglia are responsible for transducing itch stimuli to the central nervous system (CNS) [1, 40, 45] . TRPV1-expressing C-fibers are required for both histamine-dependent and -independent itch [39, 52] . Histamine, released from mast cells, binds H1 and H4 receptors on nerve terminals in skin to elicit itch via activation of phospholipase C β3 and TRPV1 [10] . Of interest, histamine-independent itch induced by chloroquine (an antimalarial drug and an agonist of the sensory neuron-specific G protein-coupled receptor MrgprA3 and BAM8-22, an endogenous agonist of MrgprC11), requires TRPA1
but not TRPV1 [11, 42] . In the spinal cord, gastrin-releasing peptide (GRP) released from primary TRPV1-expressing C-fibers, may activate GRP receptor-expressing neurons in superficial laminae of the dorsal horn to elicit the itching sensation [20, 21] .
Although pain is known to suppress itch in physiological and acute conditions [53] , pain and itch also share remarkable similarities, especially in clinical and pathological conditions [1, 45, 54] . First, both are unpleasant sensory experiences and are multidimensional, including sensory discriminative, affective and motivational components [40] .
Second, both peripheral sensitization of primary sensory neurons and central sensitization of spinal cord and other CNS neurons are implicated in pain and itch hypersensitivity in pathological conditions [54] [55] [56] [57] . Third, similar inflammatory mediators and neurotransmitters are involved in both chronic itch and chronic pain, including opioids, proteases, and substance P, as well as their respective receptors such as μ-and κ-opioid receptors, protease-activated receptor PAR-2, and neurokinin 1 receptors [58] . Finally, oxidative stress has been demonstrated to contribute to the genesis of peripheral and central sensitization related to chronic pain, and antioxidant treatment attenuates pain behavior in animal models of inflammatory [18] and neuropathic pain [19] .
In parallel, we demonstrated in this study that oxidative challenges elicited itch behavior in mice and antioxidants attenuated the oxidant-induced itch. Thus, our results support the hypothesis that oxidative stress is positively correlated with both pain and itch.
TRP channels, such as TRPV1, TRPV3 and TRPA1, play key roles in pain and itch signal transduction in sen-sory neurons [42, [59] [60] [61] [62] . Previous reports demonstrated that TRPV1 mediates histamine-induced itch [61] while TRPA1
mediates histamine-independent itch in mice [42] . Our present work showed that TRPA1, but not TRPV1, mediated oxidative challenge-induced itch in mice, which was also independent of histamine. Oxidative stress results from metabolic activity or environmental stimuli, such as ultraviolet radiation, chemotherapeutic agents and hyperthermia, and produces highly reactive chemicals (e.g. H 2 O 2 ) and oxidizing lipid products (e.g. 4-hydroxynonenal) [14] , which are known to activate TRPA1, but not TRPV1 [43, 44, 63] .
Thus, endogenous TRPA1 agonists, such as H 2 O 2 and 4-hydroxynonenal, produced by oxidative stress, activate TRPA1 on sensory neurons to elicit or/and modulate pain and itch signaling. TRPA1 is expressed by a subset of TRPV1-expressing populations [40, 64, 65] . Here, we found that ablation of TRPV1-expressing C-fibers almost abolished oxidative challenge-induced itch, which may be attributed to the elimination of TRPA1-expressing neurons within the TRPV1 population. Both our pharmacological and genetic evidence support an essential role of TRPA1 but not TRPV1 in mediating oxidant-induced pruritus: first, the TRPA1 antagonist HC-030031 reduced oxidant-induced itch; and second, H 2 O 2 -induced scratching was largely prevented in Trpa1 -/-mice but intact in Trpv1 -/-mice.
In summary, we have demonstrated that oxidative challenges are sufficient to induce scratching behavior in mice via activation of TRPA1 in TRPV1-positive C-fibers. Oxidative stress is not only present in neurodegenerative conditions [66, 67] , but also exists in chronic itch conditions associated with atopic dermatitis, psoriasis, chronic renal failure, cholestasis, and diabetes [24] [25] [26] . Moreover, our findings
showed that the oxidative stress-induced itch response is largely independent of histamine, consistent with the clinical observation that chronic itch associated with oxidative stress is resistant to antihistamine treatment. Although further investigation is needed to establish that oxidative stress also drives chronic itch, our findings strongly suggest that oxidative stress is a novel mechanism for pruritus. Targeting oxidative stress by antioxidants or blocking TRPA1 activation by selective TRPA1 antagonists may lead to the development of novel and effective anti-itch therapies.
